Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Multiplex Biomarker Imaging Market: North America Expected to be the Most Attractive Regional Market During the Forecast Period: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027

Table of Content

Table Of Content

1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition

3. Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Regulatory Scenario

4. North America Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
4.5.1. Instruments
4.5.1.1. Quantitative Pathology Imaging System
4.5.1.2. Immunofluorescence Slide Scanner
4.5.1.3. Multispectral Imaging Systems
4.5.1.4. Toponome imaging System
4.5.2. Software
4.5.3. Services
4.5.3.1. Installation & Integration Services
4.5.3.2. Maintenance Service
4.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
4.6.1. Instruments
4.6.1.1. Quantitative Pathology Imaging System
4.6.1.2. Immunofluorescence Slide Scanner
4.6.1.3. Multispectral Imaging Systems
4.6.1.4. Toponome imaging System
4.6.2. Software
4.6.3. Services
4.6.3.1. Installation & Integration Services
4.6.3.2. Maintenance Service
4.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
4.7.1. Immunohistochemistry (IHC) Assay
4.7.2. Fluorescent In Situ Hybridization (FISH) Assay
4.7.3. Tissue Microarray (TMA) Assay
4.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
4.8.1. Immunohistochemistry (IHC) Assay
4.8.2. Fluorescent In Situ Hybridization (FISH) Assay
4.8.3. Tissue Microarray (TMA) Assay
4.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
4.9.1. Research
4.9.2. Clinical Diagnostics
4.10.Market Size (US$ Mn) Forecast, by Application, 2017-2027
4.10.1. Research
4.10.2. Clinical Diagnostics
4.11.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
4.11.1. Translational Laboratories
4.11.2. Biopharmaceutical Companies
4.11.3. Academic Institutes
4.12.Market Size (US$ Mn) Forecast, by Application, 2017-2027
4.12.1. Translational Laboratories
4.12.2. Biopharmaceutical Companies
4.12.3. Academic Institutes
4.13.Drivers and Restraints: Impact Analysis
4.14. Market Attractiveness Analysis
4.14.1. By Country
4.14.2. By Component Type
4.14.3. By Imaging Technique
4.14.4. Application
4.14.5. End User
4.15. Key Representative Market Presence (Intensity Map)

5. Latin America Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Argentina
5.3.4. Rest of Latin America
5.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Argentina
5.4.4. Rest of Latin America
5.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
5.5.1. Instruments
5.5.1.1. Quantitative Pathology Imaging System
5.5.1.2. Immunofluorescence Slide Scanner
5.5.1.3. Multispectral Imaging Systems
5.5.1.4. Toponome imaging System
5.5.2. Software
5.5.3. Services
5.5.3.1. Installation & Integration Services
5.5.3.2. Maintenance Service
5.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
5.6.1. Instruments
5.6.1.1. Quantitative Pathology Imaging System
5.6.1.2. Immunofluorescence Slide Scanner
5.6.1.3. Multispectral Imaging Systems
5.6.1.4. Toponome imaging System
5.6.2. Software
5.6.3. Services
5.6.3.1. Installation & Integration Services
5.6.3.2. Maintenance Service
5.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
5.7.1. Immunohistochemistry (IHC) Assay
5.7.2. Fluorescent In Situ Hybridization (FISH) Assay
5.7.3. Tissue Microarray (TMA) Assay
5.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
5.8.1. Immunohistochemistry (IHC) Assay
5.8.2. Fluorescent In Situ Hybridization (FISH) Assay
5.8.3. Tissue Microarray (TMA) Assay
5.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
5.9.1. Research
5.9.2. Clinical Diagnostics
5.10.Market Size (US$ Mn) Forecast, by Application, 2017-2027
5.10.1. Research
5.10.2. Clinical Diagnostics
5.11.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
5.11.1. Translational Laboratories
5.11.2. Biopharmaceutical Companies
5.11.3. Academic Institutes
5.12.Market Size (US$ Mn) Forecast, by Application, 2017-2027
5.12.1. Translational Laboratories
5.12.2. Biopharmaceutical Companies
5.12.3. Academic Institutes
5.13.Drivers and Restraints: Impact Analysis
5.14. Market Attractiveness Analysis
5.14.1. By Country
5.14.2. By Component Type
5.14.3. By Imaging Technique
5.14.4. Application
5.14.5. End User
5.15. Key Representative Market Presence (Intensity Map)

6. Western Europe Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
6.3.1. U.K.
6.3.2. Germany
6.3.3. France
6.3.4. Italy
6.3.5. Spain
6.3.6. Nordics
6.3.7. BENELUX
6.3.8. Rest of Western Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
6.4.1. U.K.
6.4.2. Germany
6.4.3. France
6.4.4. Italy
6.4.5. Spain
6.4.6. Nordics
6.4.7. BENELUX
6.4.8. Rest of Western Europe
6.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
6.5.1. Instruments
6.5.1.1. Quantitative Pathology Imaging System
6.5.1.2. Immunofluorescence Slide Scanner
6.5.1.3. Multispectral Imaging Systems
6.5.1.4. Toponome imaging System
6.5.2. Software
6.5.3. Services
6.5.3.1. Installation & Integration Services
6.5.3.2. Maintenance Service
6.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
6.6.1. Instruments
6.6.1.1. Quantitative Pathology Imaging System
6.6.1.2. Immunofluorescence Slide Scanner
6.6.1.3. Multispectral Imaging Systems
6.6.1.4. Toponome imaging System
6.6.2. Software
6.6.3. Services
6.6.3.1. Installation & Integration Services
6.6.3.2. Maintenance Service
6.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
6.7.1. Immunohistochemistry (IHC) Assay
6.7.2. Fluorescent In Situ Hybridization (FISH) Assay
6.7.3. Tissue Microarray (TMA) Assay
6.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
6.8.1. Immunohistochemistry (IHC) Assay
6.8.2. Fluorescent In Situ Hybridization (FISH) Assay
6.8.3. Tissue Microarray (TMA) Assay
6.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
6.9.1. Research
6.9.2. Clinical Diagnostics
6.10.Market Size (US$ Mn) Forecast, by Application, 2017-2027
6.10.1. Research
6.10.2. Clinical Diagnostics
6.11.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
6.11.1. Translational Laboratories
6.11.2. Biopharmaceutical Companies
6.11.3. Academic Institutes
6.12.Market Size (US$ Mn) Forecast, by Application, 2017-2027
6.12.1. Translational Laboratories
6.12.2. Biopharmaceutical Companies
6.12.3. Academic Institutes
6.13.Drivers and Restraints: Impact Analysis
6.14. Market Attractiveness Analysis
6.14.1. By Country
6.14.2. By Component Type
6.14.3. By Imaging Technique
6.14.4. Application
6.14.5. End User
6.15. Key Representative Market Presence (Intensity Map)

7. Eastern Europe Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
7.2.1. Russia
7.2.2. Poland
7.2.3. Rest of Eastern Europe
7.3. Market Size (US$ Mn) Forecast By Country,2017-2027
7.3.1. Russia
7.3.2. Poland
7.3.3. Rest of Eastern Europe
7.4. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
7.4.1. Instruments
7.4.1.1. Quantitative Pathology Imaging System
7.4.1.2. Immunofluorescence Slide Scanner
7.4.1.3. Multispectral Imaging Systems
7.4.1.4. Toponome imaging System
7.4.2. Software
7.4.3. Services
7.4.3.1. Installation & Integration Services
7.4.3.2. Maintenance Service
7.5. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
7.5.1. Instruments
7.5.1.1. Quantitative Pathology Imaging System
7.5.1.2. Immunofluorescence Slide Scanner
7.5.1.3. Multispectral Imaging Systems
7.5.1.4. Toponome imaging System
7.5.2. Software
7.5.3. Services
7.5.3.1. Installation & Integration Services
7.5.3.2. Maintenance Service
7.6. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
7.6.1. Immunohistochemistry (IHC) Assay
7.6.2. Fluorescent In Situ Hybridization (FISH) Assay
7.6.3. Tissue Microarray (TMA) Assay
7.7. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
7.7.1. Immunohistochemistry (IHC) Assay
7.7.2. Fluorescent In Situ Hybridization (FISH) Assay
7.7.3. Tissue Microarray (TMA) Assay
7.8. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
7.8.1. Research
7.8.2. Clinical Diagnostics
7.9. Market Size (US$ Mn) Forecast, by Application, 2017-2027
7.9.1. Research
7.9.2. Clinical Diagnostics
7.10.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
7.10.1. Translational Laboratories
7.10.2. Biopharmaceutical Companies
7.10.3. Academic Institutes
7.11.Market Size (US$ Mn) Forecast, by Application, 2017-2027
7.11.1. Translational Laboratories
7.11.2. Biopharmaceutical Companies
7.11.3. Academic Institutes
7.12. Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Component Type
7.12.3. By Imaging Technique
7.12.4. Application
7.12.5. End User
7.13. Key Representative Market Presence (Intensity Map)

8. Asia-Pacific Excluding Japan (APEJ) Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.2.3. Trends
8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
8.3.1. China
8.3.2. India
8.3.3. Australia and New Zealand
8.3.4. ASEAN
8.3.5. Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
8.4.1. China
8.4.2. India
8.4.3. Australia and New Zealand
8.4.4. ASEAN
8.4.5. Rest of APEJ
8.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
8.5.1. Instruments
8.5.1.1. Quantitative Pathology Imaging System
8.5.1.2. Immunofluorescence Slide Scanner
8.5.1.3. Multispectral Imaging Systems
8.5.1.4. Toponome imaging System
8.5.2. Software
8.5.3. Services
8.5.3.1. Installation & Integration Services
8.5.3.2. Maintenance Service
8.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
8.6.1. Instruments
8.6.1.1. Quantitative Pathology Imaging System
8.6.1.2. Immunofluorescence Slide Scanner
8.6.1.3. Multispectral Imaging Systems
8.6.1.4. Toponome imaging System
8.6.2. Software
8.6.3. Services
8.6.3.1. Installation & Integration Services
8.6.3.2. Maintenance Service
8.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
8.7.1. Immunohistochemistry (IHC) Assay
8.7.2. Fluorescent In Situ Hybridization (FISH) Assay
8.7.3. Tissue Microarray (TMA) Assay
8.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
8.8.1. Immunohistochemistry (IHC) Assay
8.8.2. Fluorescent In Situ Hybridization (FISH) Assay
8.8.3. Tissue Microarray (TMA) Assay
8.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
8.9.1. Research
8.9.2. Clinical Diagnostics
8.10.Market Size (US$ Mn) Forecast, by Application, 2017-2027
8.10.1. Research
8.10.2. Clinical Diagnostics
8.11.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
8.11.1. Translational Laboratories
8.11.2. Biopharmaceutical Companies
8.11.3. Academic Institutes
8.12.Market Size (US$ Mn) Forecast, by Application, 2017-2027
8.12.1. Translational Laboratories
8.12.2. Biopharmaceutical Companies
8.12.3. Academic Institutes
8.13.Drivers and Restraints: Impact Analysis
8.14. Market Attractiveness Analysis
8.14.1. By Country
8.14.2. By Component Type
8.14.3. By Imaging Technique
8.14.4. Application
8.14.5. End User
8.15. Key Representative Market Presence (Intensity Map)

9. Japan Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
9.2.1. Instruments
9.2.1.1. Quantitative Pathology Imaging System
9.2.1.2. Immunofluorescence Slide Scanner
9.2.1.3. Multispectral Imaging Systems
9.2.1.4. Toponome imaging System
9.2.2. Software
9.2.3. Services
9.2.3.1. Installation & Integration Services
9.2.3.2. Maintenance Service
9.3. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
9.3.1. Instruments
9.3.1.1. Quantitative Pathology Imaging System
9.3.1.2. Immunofluorescence Slide Scanner
9.3.1.3. Multispectral Imaging Systems
9.3.1.4. Toponome imaging System
9.3.2. Software
9.3.3. Services
9.3.3.1. Installation & Integration Services
9.3.3.2. Maintenance Service
9.4. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
9.4.1. Immunohistochemistry (IHC) Assay
9.4.2. Fluorescent In Situ Hybridization (FISH) Assay
9.4.3. Tissue Microarray (TMA) Assay
9.5. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
9.5.1. Immunohistochemistry (IHC) Assay
9.5.2. Fluorescent In Situ Hybridization (FISH) Assay
9.5.3. Tissue Microarray (TMA) Assay
9.6. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
9.6.1. Research
9.6.2. Clinical Diagnostics
9.7. Market Size (US$ Mn) Forecast, by Application, 2017-2027
9.7.1. Research
9.7.2. Clinical Diagnostics
9.8. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
9.8.1. Translational Laboratories
9.8.2. Biopharmaceutical Companies
9.8.3. Academic Institutes
9.9. Market Size (US$ Mn) Forecast, by Application, 2017-2027
9.9.1. Translational Laboratories
9.9.2. Biopharmaceutical Companies
9.9.3. Academic Institutes
9.10. Market Attractiveness Analysis
9.10.1. By Component Type
9.10.2. By Imaging Technique
9.10.3. Application
9.10.4. End User
9.11. Key Representative Market Presence (Intensity Map)

10. Middle East and Africa Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
10.1. Introduction
10.2. Regional Market Dynamics
10.2.1. Drivers
10.2.2. Restraints
10.2.3. Trends
10.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
10.3.1. GCC Countries
10.3.2. South Africa
10.3.3. Rest of MEA
10.4. Market Size (US$ Mn) Forecast By Country, 2017- 2027
10.4.1. GCC Countries
10.4.2. South Africa
10.4.3. Rest of MEA
10.5.Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
10.5.1. Instruments
10.5.1.1. Quantitative Pathology Imaging System
10.5.1.2. Immunofluorescence Slide Scanner
10.5.1.3. Multispectral Imaging Systems
10.5.1.4. Toponome imaging System
10.5.2. Software
10.5.3. Services
10.5.3.1. Installation & Integration Services
10.5.3.2. Maintenance Service
10.6.Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
10.6.1. Instruments
10.6.1.1. Quantitative Pathology Imaging System
10.6.1.2. Immunofluorescence Slide Scanner
10.6.1.3. Multispectral Imaging Systems
10.6.1.4. Toponome imaging System
10.6.2. Software
10.6.3. Services
10.6.3.1. Installation & Integration Services
10.6.3.2. Maintenance Service
10.7.Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
10.7.1. Immunohistochemistry (IHC) Assay
10.7.2. Fluorescent In Situ Hybridization (FISH) Assay
10.7.3. Tissue Microarray (TMA) Assay
10.8.Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
10.8.1. Immunohistochemistry (IHC) Assay
10.8.2. Fluorescent In Situ Hybridization (FISH) Assay
10.8.3. Tissue Microarray (TMA) Assay
10.9.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
10.9.1. Research
10.9.2. Clinical Diagnostics
10.10. Market Size (US$ Mn) Forecast, by Application, 2017-2027
10.10.1. Research
10.10.2. Clinical Diagnostics
10.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
10.11.1. Translational Laboratories
10.11.2. Biopharmaceutical Companies
10.11.3. Academic Institutes
10.12. Market Size (US$ Mn) Forecast, by Application, 2017-2027
10.12.1. Translational Laboratories
10.12.2. Biopharmaceutical Companies
10.12.3. Academic Institutes
10.13. Drivers and Restraints: Impact Analysis
10.14. Market Attractiveness Analysis
10.14.1. By Country
10.14.2. By Component Type
10.14.3. By Imaging Technique
10.14.4. Application
10.14.5. End User
10.15. Key Representative Market Presence (Intensity Map)

11. Forecast Factors: Relevance and Impact

12. Forecast Assumptions

13. Competition Landscape
13.1. Competition Dashboard
13.2. Company Share Analysis
13.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments and SWOT Analysis)
13.3.1. Perkin Elmer, Inc.
13.3.2. Bio-rad Laboratories Inc.
13.3.3. Thermo Fisher Scientific, Inc.
13.3.4. Abcam plc.
13.3.5. Merck KGaA
13.3.6. Illumina Inc.
13.3.7. Leica Biosystems Nussloch GmbH
13.3.8. Ventana Medical Systems, Inc.
13.3.9. Aushon BioSystems Ltd.
13.3.10. MicroConstants, Inc.
13.3.11. ToposNomos Ltd.

14. Global Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027, By Region
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2016
14.2.1. North America
14.2.2. Latin America
14.2.3. Western Europe
14.2.4. Eastern Europe
14.2.5. Asia Pacific Excluding Japan
14.2.6. Japan
14.2.7. Middle East and Africa
14.3. Market Size (US$ Mn) Forecast By Region, 2017-2027
14.3.1. North America
14.3.2. Latin America
14.3.3. Western Europe
14.3.4. Eastern Europe
14.3.5. Asia Pacific Excluding Japan
14.3.6. Japan
14.3.7. Middle East and Africa
14.4. Market Attractiveness Analysis By Region

15. Global Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027, By Component Type
15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
15.2.1. Instruments
15.2.1.1. Quantitative Pathology Imaging System
15.2.1.2. Immunofluorescence Slide Scanner
15.2.1.3. Multispectral Imaging Systems
15.2.1.4. Toponome imaging System
15.2.2. Software
15.2.3. Services
15.2.3.1. Installation & Integration Services
15.2.4. Maintenance Service
15.3. Market Size (US$ Mn) and Volume Forecast By Component Type,2017-2027
15.3.1. Instruments
15.3.1.1. Quantitative Pathology Imaging System
15.3.1.2. Immunofluorescence Slide Scanner
15.3.1.3. Multispectral Imaging Systems
15.3.1.4. Toponome imaging System
15.3.2. Software
15.3.3. Services
15.3.3.1. Installation & Integration Services
15.3.4. Maintenance Service
15.4. Market Attractiveness Analysis by Component Type

16. Global Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027, By Imaging Technique
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis, by Imaging Technique, 2012-2016
16.2.1. Immunohistochemistry (IHC) Assay
16.2.2. Fluorescent In Situ Hybridization (FISH) Assay
16.2.3. Tissue Microarray (TMA) Assay
16.3. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
16.3.1. Immunohistochemistry (IHC) Assay
16.3.2. Fluorescent In Situ Hybridization (FISH) Assay
16.3.3. Tissue Microarray (TMA) Assay
16.4. Market Attractiveness Analysis by Imaging Technique 

17. Global Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027, By Application
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis, by Application, 2012-2016
17.2.1. Research
17.2.2. Clinical Diagnostics
17.3. Market Size (US$ Mn) Forecast, by Application, 2017-2027
17.3.1. Research
17.3.2. Clinical Diagnostics
17.4. Market Attractiveness Analysis by Application

18. Global Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027, By End User
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis, by End User, 2012-2016
18.2.1. Translational Laboratories
18.2.2. Biopharmaceutical Companies
18.2.3. Academic Institutes
18.3. Market Size (US$ Mn) Forecast, by End User, 2017-2027
18.3.1. Translational Laboratories
18.3.2. Biopharmaceutical Companies
18.3.3. Academic Institutes
18.4. Market Attractiveness Analysis by End User

19. Global Market Analysis 2012–2016 and Forecast 2017–2027
19.1. Market Size and Y-o-Y Growth
19.2. Absolute $ Opportunity

20. Assumptions and Acronyms Used

21. Research Methodology

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote